XML 63 R49.htm IDEA: XBRL DOCUMENT
v3.23.1

Note 6 - Goodwill and Intangible Assets - Change in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Mar. 31, 2023 | Mar. 31, 2022
Goodwill | $ 291,166 | $ 160,841
Effect of foreign currency translation | (7,543) | (5,555)
Goodwill | 286,444 | 291,166
Agena [Member] |  |
Goodwill adjustment related to acquisition |  | 135,880
Measurement period adjustment - Agena Acquisition | (152) |
Belyntic Acquisition [Member] |  |
Goodwill adjustment related to acquisition | 2,973 |
Clinical Genomics [Member] |  |
Goodwill | 135,811 |
Clinical Genomics [Member] | Agena [Member] |  |
Measurement period adjustment - Agena Acquisition | (152) |
Clinical Genomics [Member] | Belyntic Acquisition [Member] |  |
Goodwill adjustment related to acquisition | 0 |
Clinical Genomics [Member] | Operating Segments [Member] |  |
Goodwill | 135,914 | 0
Effect of foreign currency translation | 49 | 34
Goodwill |  | 135,914
Clinical Genomics [Member] | Operating Segments [Member] | Agena [Member] |  |
Goodwill adjustment related to acquisition |  | 135,880
Sterilization and Disinfection Control [Member] |  |
Goodwill | 29,559 |
Sterilization and Disinfection Control [Member] | Agena [Member] |  |
Measurement period adjustment - Agena Acquisition | 0 |
Sterilization and Disinfection Control [Member] | Belyntic Acquisition [Member] |  |
Goodwill adjustment related to acquisition | 0 |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] |  |
Goodwill | 29,750 | 30,153
Effect of foreign currency translation | (191) | (403)
Goodwill |  | 29,750
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Agena [Member] |  |
Goodwill adjustment related to acquisition |  | 0
Biopharmaceutical Development [Member] |  |
Goodwill | 83,857 |
Biopharmaceutical Development [Member] | Agena [Member] |  |
Measurement period adjustment - Agena Acquisition | 0 |
Biopharmaceutical Development [Member] | Belyntic Acquisition [Member] |  |
Goodwill adjustment related to acquisition | 2,973 |
Biopharmaceutical Development [Member] | Operating Segments [Member] |  |
Goodwill | 88,265 | 93,399
Effect of foreign currency translation | (7,381) | (5,134)
Goodwill |  | 88,265
Biopharmaceutical Development [Member] | Operating Segments [Member] | Agena [Member] |  |
Goodwill adjustment related to acquisition |  | 0
Calibration Solutions [Member] |  |
Goodwill | 37,217 |
Calibration Solutions [Member] | Agena [Member] |  |
Measurement period adjustment - Agena Acquisition | 0 |
Calibration Solutions [Member] | Belyntic Acquisition [Member] |  |
Goodwill adjustment related to acquisition | 0 |
Calibration Solutions [Member] | Operating Segments [Member] |  |
Goodwill | 37,237 | 37,289
Effect of foreign currency translation | $ (20) | (52)
Goodwill |  | 37,237
Calibration Solutions [Member] | Operating Segments [Member] | Agena [Member] |  |
Goodwill adjustment related to acquisition |  | $ 0

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details
Name: | us-gaap_GoodwillAcquiredDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details
Name: | us-gaap_GoodwillForeignCurrencyTranslationGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16 + Details
Name: | us-gaap_GoodwillPurchaseAccountingAdjustments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mlab_AgenaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mlab_BelynticAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |